LUPIN

US diabetes drug launch draws USFDA attention

launches Liraglutide Injection in the US, marked as a significant milestone in its complex injectables portfolio. Meanwhile, USFDA issues four observations to the company's Pithampur unit during inspection, sparking compliance issues. Lupin is working to resolve the issues with the FDA.